Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Long-Term Outcomes of Teplizumab in Routine Clinical Care
Long-Term Outcomes of Teplizumab in Routine Clinical Care

NCT07360080

RecruitingN/A

Sponsor: Sanofi

Conditions: Type 1 Diabetes

Interventions: Teplizumab

Countries: United States, Israel, United Arab Emirates

This is an observational, prospective cohort study designed to evaluate the outcomes after teplizumab treatment in participants with Stage 2 Type 1 Diabetes (T1D) for delaying the onset of Stage 3 T1D. The study will monitor participants receiving teplizumab as part of routine clinical care across multiple sites. Additionally, patient-reported outcomes (PROs) will be evaluated to further assess the treatment's impact on participant's quality of life including emotional and psychosocial aspects associated with T1D. This approach will provide a more comprehensive understanding of how the treatment performs over time and across diverse patient populations, providing valuable insights into the sustained effects of teplizumab and offering a real world picture of its impact on the long-term management of T1D.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria -

* Participants who have received at least 1 teplizumab infusion within 6 weeks prior to enrollment.
* Participants must have a confirmed diagnosis of Stage 2 T1D according to the treating physician at the time of the first infusion of teplizumab.

(Note: Participants who progress to Stage 3 T1D by Week 6 will still be eligible, provided they were in Stage 2 at the time of the first teplizumab infusion.)

• Participants (or their legal guardians, as applicable) who provide appropriate written or electronic informed consent/assent as applicable for the age of the participant and as per local regulations.

Exclusion Criteria -

* Participants who had participated in a previous clinical trial for teplizumab.
* Participants enrolled in a clinical trial within 6 months prior to study enrollment.

(Note: Participants enrolled in other observational studies may be included.)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Locations (8)
  • Atlanta, Georgia, United States
  • Atlanta, Georgia, United States
  • Syosset, New York, United States
  • Sandy City, Utah, United States
  • Petah Tikva, Israel
  • Ramat Gan, Israel
  • Ramat Gan, Israel
  • Abu Dhabi, United Arab Emirates